This topic contains a solution. Click here to go to the answer

Author Question: This experimental design (R) X Y2 (R) - Y2 is recommended for studies in which a. ... (Read 46 times)

mcmcdaniel

  • Hero Member
  • *****
  • Posts: 550
This experimental design
 
  (R)
  X
  Y2
  (R)
  -
  Y2
 
  is recommended for studies in which
 
  a. pretest reactivity is likely to occur.
  c. a large sample is available.
  b. no control group is available.
  d. only a small sample is available.

Question 2

After an experiment was in progress, a researcher learned that the experimental group had a more experienced teacher than did the control group. Should the researcher mention this fact in the research report?
 
  a. Yes, any factor which might affect the internal validity of the experiment should be reported.
  b. No, it is not necessary for the reader to know all the details about problems which arise during the course of a study



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

scrocafella

  • Sr. Member
  • ****
  • Posts: 346
Answer to Question 1

A

Answer to Question 2

ANS: A




mcmcdaniel

  • Member
  • Posts: 550
Reply 2 on: Jun 20, 2018
Excellent


kishoreddi

  • Member
  • Posts: 329
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

Parkinson's disease is both chronic and progressive. This means that it persists over a long period of time and that its symptoms grow worse over time.

Did you know?

Human kidneys will clean about 1 million gallons of blood in an average lifetime.

Did you know?

Fatal fungal infections may be able to resist newer antifungal drugs. Globally, fungal infections are often fatal due to the lack of access to multiple antifungals, which may be required to be utilized in combination. Single antifungals may not be enough to stop a fungal infection from causing the death of a patient.

Did you know?

The FDA recognizes 118 routes of administration.

Did you know?

Today, nearly 8 out of 10 pregnant women living with HIV (about 1.1 million), receive antiretrovirals.

For a complete list of videos, visit our video library